Atrial Fibrillation Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Atrial Fibrillation Market: By Type (Surgical, and Non-Surgical), By Technology (Radiofrequency, Laser, Cryotherapy, and Others), By End user (Hospitals, Specialty Clinics, and Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The atrial fibrillation market is anticipated to be valued at USD 1,945.6 million in 2021 and is expanded to grow at a significant CAGR of 7.2% over 2022-2028. Atrial fibrillation is the most common problem with the heartbeat’s rate or rhythm. Atrial fibrillation is caused by disordered signals that cause the two top chambers of the heart (the atria) to squeeze very quickly and out of sync. The increased prevalence of heart attacks and high blood pressure among people is driving the atrial fibrillation industry. Furthermore, the market is also boosted by the prevalence of obesity, diabetes, and metabolic syndrome. The market is predicted to develop due to the growing patient pool and the geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure. The key players are manufacturing advanced catheter ablation for the treatment of atrial fibrillation and reducing the risk of stroke in patients, which has paved the way for lucrative opportunities in the industry. A favorable regulatory scenario would also propel growth in this market. Due to an increase in the adoption of cardiac monitoring systems during the treatment of atrial fibrillation, the surgical segment generated the most revenue in 2020. By end-user, the hospital segment registered the highest revenue in 2021, owning to the increased adoption of laser and radiofrequency methods for catheter ablation. An increase in number of patients with arrhythmia or an irregular heartbeat problem has resulted in a growth in demand for cardiac monitors.

Recent Market Developments:

In Feb 2022, Boston Scientific Corporation announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.

In Jan 2022, Medtronic plc, a global leader in healthcare technology, announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).

Atrial Fibrillation Market

MARKET SUMMARY
-
7.2% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.2%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Atrial Fibrillation Market

  • The atrial fibrillation market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The atrial fibrillation market is segmented based on type, technology, end user, and geography.
Key Players
  • Pfizer, Inc.
  • Sanofi
  • Novartis
  • Eli Lilly and Company
  • AbbVie Inc.
Atrial Fibrillation Market

Dynamics

Because of the rising patient pool and the geriatric population suffering from lifestyle diseases such as atherosclerosis and heart failure, the market is expected to rise. Furthermore, due to the rising prevalence of obesity, the number of persons suffering from atrial fibrillation is rising. As a result, it’s thought that increasing obesity rates are adding to the market’s expansion. Scarcity of experienced professionals and adverse preference for pharmacological treatments over atrial fibrillation devices are the main factors hampering the global atrial fibrillation market.


North-America Got Significant Share

Atrial Fibrillation Market

Due to an increasing patient pool, technological improvements, and the availability of favourable insurance plans, North America atrial fibrillation is expected to have a significant market share in the global market in the next years. Furthermore, A growing number of patients affected with atrial fibrillation in the European countries, acceptable regulations supporting the increasing utilization of catheter, and surgical ablation treatments of atrial fibrillation are the factors escalating the atrial fibrillation surgery market of Europe.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
Atrial Fibrillation Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Johnson & Johnson Private Limited.,
  • Boston Scientific Corporation
  • Medtronic
  • BIOTRONIK SE & Co. KG
  • CardioFocus
  • Abbott
  • Koninklijke Philips N.V.,

Description

The atrial fibrillation market is anticipated to be valued at USD 1,945.6 million in 2021 and is expanded to grow at a significant CAGR of 7.2% over 2022-2028. Atrial fibrillation is the most common problem with the heartbeat’s rate or rhythm. Atrial fibrillation is caused by disordered signals that cause the two top chambers of the heart (the atria) to squeeze very quickly and out of sync. The increased prevalence of heart attacks and high blood pressure among people is driving the atrial fibrillation industry. Furthermore, the market is also boosted by the prevalence of obesity, diabetes, and metabolic syndrome. The market is predicted to develop due to the growing patient pool and the geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure. The key players are manufacturing advanced catheter ablation for the treatment of atrial fibrillation and reducing the risk of stroke in patients, which has paved the way for lucrative opportunities in the industry. A favorable regulatory scenario would also propel growth in this market. Due to an increase in the adoption of cardiac monitoring systems during the treatment of atrial fibrillation, the surgical segment generated the most revenue in 2020. By end-user, the hospital segment registered the highest revenue in 2021, owning to the increased adoption of laser and radiofrequency methods for catheter ablation. An increase in number of patients with arrhythmia or an irregular heartbeat problem has resulted in a growth in demand for cardiac monitors.

Recent Market Developments:

In Feb 2022, Boston Scientific Corporation announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.

In Jan 2022, Medtronic plc, a global leader in healthcare technology, announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX